Screening for diabetes in indigenous populations using glycated haemoglobin: Sensitivity, specificity, post-test likelihood and risk of disease

Diabetic Medicine

Volumn 22, Issue 7, 2005, Pages 833-839

  Rowley, Kevin G ^a,d   Daniel, M ^b   O'Dea, K ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

Diabetes mellitus; Diagnosis; Glycated haemoglobin; Indigenous populations; Screening

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

ABORIGINE; ADOLESCENT; ADULT; AGED; ARTICLE; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRALIA; CANADA; DIABETES MELLITUS; DIAGNOSTIC ERRORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIANS, NORTH AMERICAN; MALE; MASS SCREENING; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PREVALENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION;

EID: 21744437893     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01447.x     Document Type: Article

References (41)

1. 1c. Diab Res Clin Pract 2000; 50: 225-230.
2. 1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care 1998; 21: 1221-1225.
3. 1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose. The Early Diabetes Intervention Program (EDIP). Diabetes Care 2001; 24: 465-471.
4. 1c) is more sensitive than fasting blood glucose as a screening test for diabetes. Diabetes Care 2000; 23: 1206-1207 (letter).
5. 1c) to screen for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 1207 (letter).
6. 1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 187-191.
7. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
8. Diabetes UK. Early identification of people with Type 2 diabetes. Diabetes UK, 2002: www.diabetes.org.uk/hcpreports/position.htm.
9. Anand AS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q et al. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 2003; 26: 290-296.
10. Daniel M, Rowley KG, O'Dea K. Fasting criteria for screening: test properties and agreement with glucose tolerance. Diab Res Clin Pract 2002; 58: 139-148.
11. Finch CF, Zimmett PZ, Alberti KGMM. Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentrations? Diabet Med 1990; 7: 603-610.
12. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance. 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. Diab Res Clin Pract 1999; 44: 21-26.
13. Daniel M, Marion SA, Sheps SB, Hertzman C, Gamble D. Variation by body mass index and age in waist-to-hip ratio associations with glycemic status in an aboriginal population at risk for type 2 diabetes mellitus in British Columbia, Canada. Am J Clin Nutr 1999; 69: 455-460.
14. Leonard D, McDermott R, O'Dea K, Rowley KG, Pensio P, Sambo E et al. Obesity, diabetes and associated cardiovascular risk factors among Torres Strait Islander people. Aust NZ J Public Health 2002; 26: 144-149.
15. Rowley KG, Daniel M, Skinner K, Skinner M, White GA, O'Dea K. Effectiveness of a community-directed 'healthy lifestyle' program in a remote Australian Aboriginal community. Aust NZ J Public Health 2000; 24: 136-144.
16. 1c specimens. Diabetes Care 1992; 15: 700-701.
17. 1c - A marker for complications of type 2 diabetes: The experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003; 41: 1182-1190.
18. National Glycohemoglobin Standardization Program. List of NGSP Certified methods. NGSP, 2004: www.missouri.edu/~diabetes/ngsp/ index.html.
19. Berry G, Armitage P. Mid-P confidence intervals: a brief review. Statistician 1995; 44: 417-423.
20. Gahlinger PM, Abramson JH. Computer Programs for Epidemiologic Analysis: PEPI 3.0. Stone Mountain, GA: USD Inc., 1998.
21. McLennan W, Madden R. The Health and Welfare of Australia's Aboriginal and Torres Strait Islander Peoples. Canberra: Australian Government Publishing Service, 1997.
22. Roberts NB, Green BN, Morris M. Potential of electrospray mass spectrometry for quantifying glycohemoglobin. Clin Chem 1997; 43: 771-778.
23. Colman PG, Goodall GI, Garcia-Webb P, Williams PF, Dunlop ME. Glycohaemoglobin: a crucial measurement in modern diabetes management. Progress towards standardisation and improved precision of measurement. Med J Aust 1997; 167: 96-98.
24. McCance DR, Hanson RL, Charles M-A, Jacobsson LTH, Pettitt DJ, Bennett PH, Knowler WC. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994; 308: 1323-1328.
25. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus. An analysis using glycosylated hemoglobin levels. JAMA 1996; 276: 1246-1252.
26. Jesudason DR, Dunstan K, Leong D, Wittert GA. Macrovascular risk and diagnostic criteria for type 2 diabetes. Diabetes Care 2003; 26: 485-490.
27. Walker KZ, O'Dea K, Nicholson GC, Muir JG. Dietary composition, body weight, and NIDDM. Comparison of high-fiber, high-carbohydrate, and modified-fat diets. Diabetes Care 1995; 18: 401-403.
28. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998; 21: 261-264.
29. Daniel M, O'Dea K, Rowley KG, McDermott R, Kelly S. Glycated haemoglobin as an indicator of social environmental stress among Indigenous versus Westernized populations. Prev Med 1999; 29: 405-413.
30. 1c levels are genetically determined even in Type 1 diabetes. Evidence from healthy and diabetic twins. Diabetes 2001; 50: 2858-2863.
31. 1c in screening for diabetes. Diabetes Care 1998; 21: 1577-1578 (letter).
32. Eberhardt MS, Flegal KM. Assessing the utility of glycated hemoglobin. Diabetes Care 1998; 21: 1578 (letter).
33. Kilpatrick ES, Keevil BG, Maylor PW. Response to Roubicek et al. and Eberhardt and Flegal. Diabetes Care 1998; 21: 1578-1579 (letter).
34. 1c in a healthy adult population. Diabetes Care 1999; 22: 1361-1363.
35. Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft Petersen P. Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 2002; 62: 623-630.
36. 1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-791.
37. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 2000; 101: 2047-52.
38. Simons LA, Friedlander Y, McCallum J, Simons J. Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. Aust NZ J Med 2000; 30: 41-47.
39. Bjørnholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Diabetes Care 1999; 22: 45-49.
40. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22: 696-699.
41. Adler AI, Neil HAW, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J 1999; 138: S353-S359.